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ABSTRACT 
The overall aim of my dissertation is to explore and develop prediction and diagnostic 
approaches to three health outcomes in vulnerable infants associated with respiratory system 
disorders: (i) Bronchopulmonary Dysplasia, the most common adverse outcome in premature 
infants, (ii) Childhood Asthma, the most common chronic condition among children, and (iii) 
Sudden Infant Death Syndrome, the third leading cause of death among all infants in the US. 
Project 1: Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that 
affects primarily premature newborns and infants. The objective of this project was to develop a 
clinical prediction model for bronchopulmonary dysplasia (BPD) in a setting where non-invasive 
ventilation is the primary choice of ventilatory support. The goal was to have the ability to 
predict the risk of BPD at an early stage of life on days 1, 7, and 21 of postnatal age to determine 
which infants will benefit most from interventions that may reduce the risk of developing BPD 
(primary prevention) and its progression.  Early administration of caffeine (within 48 hours), 
antenatal steroids, and maximum FiO2 levels were found to add significant predictive value to 
the adverse outcome of BPD and its severity. The c-statistics for the prediction model on day 1 
was 0.9062, on day 7 was 0.9270, and on day 21 was 0.9434. This model reflects 
improvements/decisions in clinical treatment advances and may enable clinicians and parents to 
make more optimal decisions on prophylactic treatment options to prevent bronchopulmonary 
dysplasia among infants. 
Project 2: Childhood asthma is an enormous challenge for clinicians because it lacks 
standardized diagnostic criteria. An inflammatory biomarker could represent a critical factor in 
developing tools that reliably predict the development of asthma in young children in daily 
clinical practice. A systematic review and meta-analysis of existing literature were conducted to 
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evaluate the efficacy of an airway inflammatory marker, serum eosinophil cationic protein, in 
diagnosing asthma among children up to 5 years of age. Although a definitive role for serum 
eosinophil cationic protein in the diagnosis of asthma in young children <5 years was not 
established in this study because of the small number of research articles, it may be a valuable 
biomarker if measured in a larger group of younger asthmatic patients, stratified by age at the 
critical time for lung development. A multicentric population-based prospective study with 
longer follow-up periods are necessary to confirm the role of serum eosinophil cationic protein in 
diagnosing childhood asthma among children less than 5 years of age. 
Project 3: This project aimed to develop a SIDS risk scoring system to identify the 
cumulative effects of maternal, infant and environmental factors that may be predictive of SIDS 
risk. A risk scoring system ranging from 0-6 was developed based on the risk factors, maternal 
age, birth weight of the infant, exposure to passive, and the duration of breastfeeding.  Factors 
making infants vulnerable to SIDS (low birth weight, young maternal age) in combination with 
the effect of exogenous stressors (passive smoking, breastfeeding) during the critical 
developmental period predicted the risk of SIDS in our model. The highest risk score of 6 had a 
sensitivity of 100% and a positive predictive value of 80.33%. For a cuff off criterion of score 1 
and lower for low-risk, the calculated risk score had a specificity of 100% and a negative 
predictive value of 92.68%. Identifying infants at high risk of SIDS enables parents and 
clinicians to be more vigilant about how to possibly prevent these infant deaths. Furthermore, 
preventing SIDS in low-risk infants will also relieve some anxiety among parents.
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CHAPTER 1: Respiratory Outcomes among Vulnerable Infants 
Children are referred to as a vulnerable population concerning their health. They have 
unique patterns of health outcomes because of different: (i) disease processes, (ii) developmental 
susceptibilities, and (iii) patterns of environmental exposures.1 Prematurity alone, or in 
combination with genetic pre-dispositions make infants further vulnerable to the environmental 
exposures.  
Approximately, 10% of live births in the US are born prematurely.2 Preterm birth is 
associated with severe respiratory illnesses causing mortality and morbidity in the first two years 
of life.3 Among the premature infants, the arrest of lung development, interference with normal 
alveolization,4 and immature neural control of respiratory system compromise the pulmonary 
function.5 
The purpose of this dissertation is to explore and develop prediction and diagnostic 
approaches to three respiratory system related outcomes in vulnerable infants: 
(i) Bronchopulmonary Dysplasia, the most common adverse outcome in premature 
infants. 
(ii) Childhood Asthma, the most common chronic condition among children. 
(iii) Sudden Infant Death Syndrome, the third leading cause of death among all infants 
in the US. 
Bronchopulmonary dysplasia: Preterm birth occurring during the canalicular stage of lung 
development is very likely to reduce pulmonary function because of poorly developed peripheral 
airways and poor maturity of cells that are important to lung maturation.6 Exposure to injuries 
due to mechanical ventilation, oxygen, and infections leads to chronic inflammation, trauma, and 
scarring of the lung tissue.7 
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Childhood asthma: Most children born preterm show catch-up growth in infancy. Recent 
studies have suggested that lower lung volumes and reduced airway caliber among premature 
infants, in association with exposure to environmental risk factors, lower the pulmonary function 
and increase the risk of childhood asthma.8,9 
Sudden infant death syndrome: It has been hypothesized that SIDS occurs during the critical 
developmental age of 2-4 months among genetically vulnerable infants exposed to 
environmental risk factors.10 Defects in respiratory control in the brainstem has been attributed to 
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Every year over 15 million babies are born premature (<37 weeks gestational age) 
worldwide, accounting for more than 1 in 10 births.1 This translates to approximately 2.4 million 
babies born before 32 weeks of postmenstrual age.2 Preterm birth remains a highly frequent 
condition around the world with significant vital and developmental consequences and has been 
relatively resistant to interventions.3  
Bronchopulmonary dysplasia (BPD) is the most common adverse outcome in very 
preterm newborns4 and is one of the most severe chronic lung diseases of infancy.5 BPD and 
prematurity have long-term impacts on pulmonary function and may increase the risk of late 
pulmonary morbidity.6 There are also concerns that newborn intensive care unit (NICU) 
survivors represent an emerging burden and future challenge for health systems and adult 
providers.7 
BPD is associated with inflammation and scarring in the lung tissue. The most common 
symptoms of bronchopulmonary dysplasia are: (i) rapid breathing, (ii) labored breathing, (iii) 
wheezing, (iv) bluish discoloration of the skin around the lips and nails due to low oxygen in the 
blood, (v) poor growth, and (vi) repeated lung infections that may require hospitalization.8 
Infants with mild BPD may not need any specialized treatment. However, infants with mild BPD 
(along with all premature infants) are at risk for apnea (especially during sleep), causing 
temporary drops in the heart rate and oxygen levels in the blood. This occurs because the 
respiratory center in the brain is not fully developed until about 44 weeks postmenstrual age. 
Infants with episodes of apnea and low heart rates often need continuous monitoring of 
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breathing, heart rate, and oxygen saturation at home. Patients with more severe disease may need 
mechanical ventilator support.9 
The prevalence of BPD ranges between 22% and 45% among very low birth weight 
infants (VLBW: Birth weight <1,500 g) in the United States, varying between newborn care 
centers, reflecting differences in patient population and infant management practices.10,11 The 
incidence of BPD in surviving infants ≤28 weeks gestational age has been relatively stable at 
40% over the last few decades.7 Annually, an estimated 10,000-15,000 new cases of BPD are 
reported in the US alone.12  
Several studies suggest increasing survival rates among infants with BPD.13,14 However, 
changes in definitions and variable approaches to the use of oxygen therapy, both influence and 
complicate interpretation of the historical data and its comparison with current statistics.15 
Although routine use of antenatal steroids and surfactant administration for preterm birth have 
significantly affected the survival of premature infants, these advances have not resulted in 
decreased rates of BPD.16 Current lung protective strategies include the use of non-invasive 
ventilation, permissive hypercapnia, and targeted use of steroids along with adjunct medical 
therapies including caffeine, and vitamin A. 
Current definition of BPD: The change in epidemiology and pathology of BPD has resulted in 
evolving definitions. In 2001, a collaborative effort by the National Institute of Child Health and 
Human Development, the National Heart, Lung, and Blood Institute, and the Office of Rare 
Diseases yielded a set of new diagnostic criteria, known colloquially as the NIH Consensus 
Definition.17 This definition categorizes BPD by severity, using a scale based on the number of 
days of supplemental oxygen use, as well as oxygen and positive pressure ventilation 
requirements at 36 weeks post-menstrual age (PMA). This distinction has helped to identify that 
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severity of BPD influences, both pulmonary and neurodevelopmental outcomes as well as the 
risk of mortality. The NIH definition of BPD17 (Figure 2.1), includes the following diagnostic 
criteria:  
1. Infants receiving treatment with oxygen for at least 28 days plus 2(a), 2(b), or 2(c) 
2. The time point of assessment at 36 weeks PMA or discharge to home, whichever comes 
first 
a. Mild BPD: Breathing room air at 36 weeks PMA or discharge, whichever comes 
first, or 
b. Moderate BPD: Need for <30% oxygen at 36 weeks PMA or discharge, whichever 
comes first, or 
c. Severe BPD: Need for ≥30% oxygen and/or positive pressure (Positive Pressure 
Ventilation or Nasal Continuous Positive Airway Pressure) at 36 weeks PMA or 
discharge, whichever comes first. 
Figure 2.1: Definition of Bronchopulmonary Dysplasia: Diagnostic Criteria.  
Gestational Age <32 weeks ≥32 weeks 
1. Time point of assessment 36 weeks PMA or discharge to 
home, whichever comes first 
>28 days but <56 days postnatal 
age or discharge to home, 
whichever comes first 
2. Treatment with oxygen >21% for at least >28 days 
 
>21% for at least >28 days 
Mild BPD Breathing room air at 36 weeks 
PMA or discharge, whichever 
comes first 
Breathing room air by 56 days of 
postnatal age or discharge, 
whichever comes first 
Moderate BPD Need* for <30% oxygen at 36 
weeks PMA or discharge, 
whichever comes first 
Need* for <30% oxygen at 56 days 
postnatal age or discharge, 
whichever comes first 
Severe BPD Need * for≥30% oxygen and/or 
positive pressure, (PPV or 
NCPAP) at 36 weeks PMA or 
discharge, whichever comes first 
Need* for≥30% oxygen and/or 
positive pressure (PPV or NCPAP) 
at 56 days postnatal age or 
discharge, whichever comes first 
Definition of abbreviations: BPD = bronchopulmonary dysplasia; NCPAP = nasal continuous positive airway 
pressure; PMA = post menstrual age; PPV = positive pressure ventilation.  
Reprinted from Davidson L, Berkelhamer S. Bronchopulmonary Dysplasia: Chronic Lung Disease of Infancy and Long-Term 







Long-term outcomes of bronchopulmonary dysplasia:  
BPD begins in the neonatal period, yet its effects may continue in the long term. Lung 
function abnormalities, especially small airway abnormalities, often persist. Prematurity itself is 
associated with an increased risk of long-term lung problems. However, in children with BPD, 
impairment of pulmonary structures and function is even higher.18  
The infants diagnosed with BPD have severely compromised quality of life because of 
prolonged intensive care hospitalization, need for oxygen therapy at discharge, and repeated 
hospital admissions due to recurrent pulmonary infections.19 These infants are also at a higher 
risk of developing psychiatric illnesses such as attention deficit hyperactivity syndrome in their 
childhood and adolescent age.20 
Respiratory outcomes: Infants with BPD are susceptible to respiratory infections 
because of underlying pulmonary dysfunction; hence, they are at higher risk of hospital 
admissions, higher readmissions, and longer duration of hospital stays. Respiratory syncytial 
virus (RSV) is a significant healthcare burden in infants with BPD.21 RSV is a common 
respiratory virus that usually causes mild, cold-like symptoms and is self-limiting in most infants 
without BPD. On the other hand, infants with BPD tend to decompensate more compared to 
preterm infants of the same gestational age without BPD. Additionally, BPD is also a risk factor 
for RSV because of underdeveloped and injured alveoli, pulmonary vasculature, and respiratory 
epithelium.22 Children and adolescents with a history of BPD are more likely to be diagnosed 
with asthma. Chronic epithelial and airway reactivity changes to the still developing infant lung, 
lung injury altering lung function and immunomodulatory changes due to RSV infection could 
also lead to childhood asthma.23 
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Neurological outcomes: Studies have identified BPD as an independent risk factor for 
poor neurological development and cerebral palsy among infants.24, 25 A possible explanation for 
this risk among BPD infants could be that these infants have frequent and prolonged periods of 
hypoxemia or apnea. 
Long-term outcomes among caregivers: In addition to higher morbidity, 
bronchopulmonary dysplasia imposes a substantial psychological and financial burden on the 
caregivers. Parental psychological distress is often manifested as depression, anxiety, and 
posttraumatic stress after NICU admission.  VLBW infants account for a high percentage of birth 
hospitalization costs. The initial hospitalization cost is 16 times higher for preterm infants with 
BPD compared to those without BPD.26 
Risk Factors: 
The pathogenesis of BPD is multifactorial, with a wide variety of pre- and post-natal 
exposures influencing lung development, injury, and repair. The following risk and protective 
factors play a significant role in the chain of prenatal and postnatal events leading to BPD. 
Table 2.1: Risk and Protective Factors for Bronchopulmonary Dysplasia 
Risk Factors Protective Factors 
Prenatal risk factors 
Chorioamnionitis  
Infant characteristics 





Post-natal risk factors 
Sepsis 
Mechanical ventilation 
Supplemental oxygen: FiO2 
Antenatal steroids 
Postnatal inhaled steroids 
Surfactant use 





A summary of the interplay between the risk and protective factors (Table 2.1) in the 
pathogenesis of BPD is presented in Figure 2.2. 
Chorioamnionitis: Chorioamnionitis (CA) is an acute inflammation of the placenta (membranes 
and chorion) in response to a microbial infection. A clinical diagnosis of chorioamnionitis 
referred to as “clinical chorioamnionitis” is made based on the characteristic clinical signs of 
intrapartum fever, maternal tachycardia, baseline fetal tachycardia, purulent amniotic fluid.27  
Chorioamnionitis (CA) is one of the leading causes of preterm delivery, which itself is a 
strong risk factor for BPD. Additionally, it has also been associated with a disturbance in the 
normal lung maturation and growth process, possibly leading to the development of BPD.28 
Histologic CA has been associated with a higher incidence of premature deliveries and an 
increased risk of sepsis.29  
Animal models showed that CA induces a lung maturation effect.30 However, it also 
causes alveolar simplification and vascular injury, making the lungs more vulnerable to postnatal 
insults.31, 32 Additional respiratory infections induce a chronic inflammatory response, 
heightening the susceptibility of these lungs to postnatal injuries like mechanical ventilation and 
hyperoxia.33 Hence, postnatal care strategies also change how chorioamnionitis relates to the 
clinical outcome of BPD. 
The independent association between chorioamnionitis and BPD is challenging to assess 
because of the variations in definition and a number of antenatal and postnatal confounding 
factors. Factors such as variability of study populations, prevalence of antenatal steroid and 
surfactant therapies, hyperoxia, mechanical ventilation, and neonatal infections confound the 




Infant demographics: Birth weight, Gestational Age, Gender, and Race: Birth weight and 
gestational age are well-established risk factors of BPD.35, 36 An inverse relation exists between 
the incidence of BPD among mechanically ventilated infants, and gestational age and 
birthweight individually.37 This supports the concept that incomplete development of lungs or 
injury during a critical window of lung development increases the likelihood of BPD. The 
compact alveoli, smaller, thicker and less vascularized epithelial surface, and chest wall softness 
in prematurely born infants contribute to their predisposition to respiratory disorders.38  
This structural immaturity has profound effects on the mechanical properties of the lung 
and, hence, the respiratory system as a whole. Premature birth during this critical period may 
result in significant alteration in lung function and physiology. The biochemical abnormality of 
surfactant deficiency is alleviated by external supplementation. However, the structural 
hypoplasia persists. Exposure of immature lungs to one or more environmental insults causes 
acute lung injury, predisposing to the development of BPD. 
There is substantial epidemiological evidence that male infants have a higher risk of 
developing BPD compared to females.39, 40 Race and ethnicity have been both independently 
strongly associated with BPD.41 A recent study conducted to study the association of race and 
ethnicity with very preterm neonatal morbidities, the authors reported 4.43 times higher risk of 
BPD among black infants and 2 times higher rate in Hispanic infants compared to white 
infants.42 A strong genetic component in the predisposition to BPD has also been described. 
These genetic variations between races may partially explain the different outcomes related to 
BPD and its severity. “One series of over 300 twins reported that genetics contributed to 




Supplemental oxygen:  Several studies have identified various toxic effects of oxygen on the 
developing tissues of the preterm infant; yet, optimal target oxygen saturation ranges have not 
been identified.44 In 2018, a meta-analysis of five large randomized clinical trials was conducted 
comparing the outcomes of oxygen saturation targets of 85%–89% and 91%–95%. The higher 
target saturation group were at a higher risk of developing bronchopulmonary dysplasia and 
retinopathy of prematurity. However, the lower target saturation group had significantly higher 
rates of death and necrotizing enterocolitis.45 
Current trends in neonatology are focusing on identifying optimal oxygen saturation 
ranges to improve infant outcomes and to reduce complications associated with oxygen use.46 
BPD and other respiratory disorders warrant supplemental oxygen. However, appropriate target 
levels of oxygen were not well established. Hyperoxia causes an increase in proliferation of type 
II alveolar cells and results in necessary alterations in surfactant development and production.47 
Since higher oxygen saturation ranges provided little to no benefit to premature infants born at 
30 weeks of gestational age and in turn created oxidative stress, lower target ranges of 85–93% 
saturated oxygen levels were implemented.48  
On the other hand, hypoxia may have a direct effect on brain growth and development. 
Hypoxemia in an effort to maintain lower target saturation levels further increases the degree of 
lung and brain damage as well as mortality.49 
Non-invasive ventilation: Gentle ventilation has been advocated for volume-targeted 
ventilation. A meta-analysis of existing evidence has supported the use of non-invasive 
ventilation as a strategy to reduce rates of BPD and ventilator-associated inflammation.12 Despite 
inconsistent results from multiple meta-analyses, the common finding of decreased risk of BPD 
strengthens recommendations for the use of non-invasive strategies as the primary choice. As a 
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result, many units are now opting for an early trial of continuous positive airway pressure 
(CPAP) to manage respiratory distress system. Non-Invasive ventilation with a set frequency, 
peak pressure, and positive end-expiratory pressure (nasal intermittent positive pressure 
ventilation) have been used as an escalation technique to avoid invasive mechanical ventilation 
when CPAP alone is not sufficient.50  
Nasal intermittent positive pressure ventilation (NIPPV) is delivered through nasal 
prongs or mask interface, in the form of (i) nasal intermittent mandatory ventilation through a 
ventilator, (ii) nasal synchronized intermittent mandatory ventilation (SIMV), or (iii) non-
synchronized from a bi-level CPAP system.51 The optimal approach and long-term outcomes 
with the use of NIPPV remain to be defined. 
Invasive mechanical ventilation: Invasive mechanical ventilation is one of the major 
contributors to the development of BPD. There is currently no ideal strategy for mechanical 
ventilation that is optimal for minimizing the risks of pulmonary sequelae.  
Antenatal steroids: Antenatal steroids accelerate the effect of endogenous corticosteroids and 
induce the production of all the components of the surfactant system.52 The role of antenatal 
steroids in facilitating clearance of lung fluid has been explained via the activation of epithelial 
sodium channels and improved lung function.53  
The 2017 American College of Obstetricians and Gynecologists guidelines recommend, 
“A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks 
and 33 6/7 weeks of gestation who are at risk of preterm delivery within 7 days, including for 
those with ruptured membranes and multiple gestations.”54 In spite of the improvement in 
respiratory outcomes among preterm infants, the role of maternal steroids in decreasing the risk 
of BPD is still controversial. A secondary analysis of the Neonatal Research Network Hospital 
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Generic Database and Follow-up protocols showed that the rate of bronchopulmonary dysplasia 
was lower in the infants born at 23 weeks' gestation (OR 0.83 95% CI: 0.57 - 1.21 but 
bronchopulmonary dysplasia in survivors was higher in infants born at 24 (OR 1.69 95% CI 1.30 
– 2.20) and 25 weeks' gestation (OR 1.33 95% CI: 1.06 – 1.67).55  
Postnatal inhaled steroids: The anti-inflammatory effect of steroids has been attributed to a 
reduced rate of BPD among infants receiving supplemental postnatal steroids. However, the 
increased risk of cerebral palsy often outweighs the benefits of systemic steroids in preventing 
BPD. In 2002, the American Academy of Pediatrics (AAP) and the Canadian Pediatric Society 
(CPS) recommended against routine use of systemic steroids for prevention of BPD.56 The safest 
and most beneficial dose, duration and route of administration of postnatal steroids is still 
debated.  
Inhaled corticosteroids were found to be safer compared to systemic steroids in reducing 
the risk of BPD as well as neurodevelopmental consequences. However, the available data are 
inadequate to support the administration of inhaled corticosteroids unequivocally. Endotracheal 
administration of corticosteroids along with surfactant among ventilated infants have shown to 
reduce the incidence of BPD among these infants.57 
 A meta-analysis of 1270 infants from 7 clinical trials showed that inhaled corticosteroids 
were associated with a significant reduction in BPD at 36 weeks postmenstrual age (RR 0.77, 
95% CI: 0.65 – 0.91). Risk of cerebral palsy among infants who are given inhaled corticosteroids 
must be weighed against the benefits of preventing BPD while making clinical decisions. For 




Surfactant: Surfactant replacement has been used as a primary prevention strategy for BPD and 
has become a standard of care for the past two decades. The primary goal of surfactant 
replacement is to reduce mortality by improving lung compliance and gas exchange in the 
immature lung of a preterm infant. Surfactant administration has also been shown to be effective 
in reducing the need for prolonged mechanical ventilation thereby decreasing the incidence of 
injury due to mechanical ventilation.59 It has also been suggested in the literature that the early 
administration of surfactant may reduce the development of BPD. Surfactant replacement has 
increased the survival of VLBW infants but the incidence and complications of new BPD remain 
the same.59, 60 
Caffeine: Caffeine is the most common methyl xanthine used in the prevention and treatment of 
apnea of prematurity. Several studies have shown that caffeine therapy initiated in very low birth 
weight (VLBW) neonates reduces the risk of developing BPD, reduces time on mechanical 
ventilation, and overall improves neonatal outcomes.61,62 The mechanism of action for 
methylxanthine in the prevention and treatment of apnea includes: (i) increased carbon dioxide 
chemoreceptor responsiveness, (ii) decreased muscle fatigability, (iii) elevated metabolic rate, 
(iv) enhanced catecholamine activity, (v) increased diaphragmatic contractility, and (vi) 
increased diuresis via tubular adenosine A1 receptors.63 The exact effect of caffeine on the 
immature alveoli is still unknown, and the studies in this particular direction are limited to 
animal models. It is hypothesized that caffeine impacts the growth factor pathway via TGF-B 
receptors and may have an effect on the development of immature lung.64 In the Caffeine for 
Apnea of Prematurity (CAP) trial, the infants randomized to caffeine therapy had a lower 
incidence of BPD, as defined by oxygen need at 36 weeks PMA.62  
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Several studies have evaluated the early initiation of caffeine on neonatal outcomes, 
including BPD and all-cause mortality, and have shown that the initiation of caffeine within the 
first 2 days of postnatal life is associated with reduced incidence of the combined outcome of 
BPD and mortality compared with start of caffeine at greater than 2 days of postnatal age.63, 65, 66 
Figure 2.2: A summary of the interplay of the above-listed risk and protective factors in the 
























Existing prediction models for BPD 
Currently, there are 31 prediction models in the literature from 1989 until 2018.67-94 A total 
of 29 models were published until 2008.  
In 2011, the NICHD Neonatal BPD Outcome Estimator was published, based on a large 
multicenter cohort between 2000-2004.92 The outcomes included the severity of BPD, and the risk 
was estimated at multiple postnatal ages. Based on a systematic review and external validation 
study conducted in 2013,95 the NICHD model developed in 2011 is one of the two best prognostic 
models.92 It is the only available model which can be used in common clinical practice. The second 
model developed by Ryan et al. 1996 has limited usefulness because it estimates the risk of BPD 
only on the 4th postnatal day and does not take into account other forms of ventilation.81 However, 
the use of caffeine and inhaled corticosteroids were not widespread during the period of 2000-
2004. The largest clinical trial for the use of caffeine (CAP trial) for apnea of prematurity was 
performed in 2006.62 
A risk scoring system for BPD was proposed in 2015 by Gursoy and colleagues, based on 
a  cohort from 2006-2009.96 This scoring system was independent of variations in clinical practice. 
It was a scoring system based on risk ratios from a logistic regression model including birth weight, 
gestational age, gender, hemodynamically significant patent ductus arteriosus, respiratory distress 
syndrome, hypotension, and intraventricular hemorrhage. Data on the use of caffeine or postnatal 
steroids in this cohort was not reported. 
Objectives 
Prediction models have a unique role in medical practice, public health, and patient care. 
The purpose of this study is to develop a clinical prediction model for bronchopulmonary 
dysplasia. The goal of BPD prediction models is to have the ability to predict the risk of BPD at 
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an early stage in life to determine which infants will benefit most from interventions that may 
reduce the risk of BPD.  In this study, the change in relative contributions of a variety of risk 
factors to the prediction of bronchopulmonary dysplasia with the administration of protective 
treatments such as caffeine, and antenatal steroids was assessed. The ability to precisely predict 
BPD will provide the ability to accurately determine which infants will benefit most for 
interventions that may reduce the risk of BPD. Thus, we hypothesized that the inclusion of caffeine 
and maternal steroids within the NICHD Neonatal BPD Outcome Estimator model may improve 
prediction of BPD in very low birth weight infants. 
 
2.2 Methods 
Data: A retrospective chart review study was performed on deidentified data obtained from the 
electronic medical records at the neonatal intensive care unit (NICU) of the OSF Children’s 
Hospital of Illinois. This study received Institutional Review Board Approval from OSF 
HealthCare. 
The inclusion criteria include infants born: (i) between 2012 and 2018, (ii) with a gestational age 
of  <30 weeks. Infants with major congenital anomalies (i.e., genetic anomaly, syndrome or 
malformation of a primary organ system) were excluded.  
Outcome variable: Bronchopulmonary dysplasia (BPD) was defined by the need for 
supplemental oxygen at a postmenstrual age of 36 weeks. BPD was defined as no BPD, mild, 
moderate, and severe based on the NIH Consensus Definition (Figure 1). The time of assessment 
for BPD was at 36 weeks of postmenstrual age. If the baby was discharged or transferred before 




Predictor variables: All the infants born with gestational age less than 30 weeks who received 
care at the OSF HealthCare NICU between 2012 and 2018 were included in the study. 
Information about gestational age, birth weight, gender, and race for each infant were obtained 
from electronic medical records. Additionally, the timing of caffeine doses was used to 
determine which infants received caffeine within 24 hours, 48 hours, and beyond 48 hours. 
Respiratory support was classified as none, nasal IMV, CPAP/Biphasic, SIMV, Assist 
control/Pressure control, and high-frequency ventilation. If an infant received more than one 
respiratory support on the day of assessment, the most aggressive form of ventilation for that day 
was entered into the dataset. The highest FiO2 levels recorded on the day of risk estimation was 
used in the model. This is different from the NICHD model where average FiO2 scores for one 
day were used. Use of surfactant among infants could not be included in the model because that 
information was missing in the available dataset. Postnatal inhaled steroids were not included 
because only 24% of the study sample received inhaled steroids and for more than 80% of those 
who received it, it was past the time of risk estimation (meaning past 21 days) 
The predictor variables, gestational age, birth weight, and maximum FiO2 levels were 
recorded as continuous variables. The remaining variables, gender, race, maternal 
chorioamnionitis (yes/no), antenatal steroids (yes/no), administration of caffeine within 24 hours 
(yes/no), administration of caffeine within 48 hours (yes/no), and type of respiratory support 
were recorded as categorical variables. 
Statistical analysis: Descriptive statistics were used to characterize the cases and controls using 
mean and standard deviation for continuous variables, and percentages for categorical variables. 
All analyses were performed using STATA 15.0 statistical software. The missing data was 
handled in STATA software by dropping the observations. Less than 1% of observations in 
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individual variables were with missing data, except for the data on antenatal steroids which had 
missing data in 21% of the infants. For the infants who were born in a different hospital and 
transferred to the OSF NICU for advanced care, information on maternal prenatal history was 
not available. 
A multinomial logistic regression model was developed to predict the risk of BPD among infants 
born at less than 30 weeks of gestational age on days 1, 7, and 21 postnatal age. The first step of 
the model development was to examine the relationship between BPD and each risk factor using 
the study data. All statistically significant variables at the alpha level 0.05 were entered into the 
model. Similar to the NICHD BPD risk estimator model, the variables retained in the model 
were not based on statistical significance but rather the contribution to the c-statistic. C-statistic 
is a standard measure of the predictive accuracy of a logistic regression model.97 It gives the 
probability of a randomly selected patient who experienced the disease (case) had a higher risk 
score than a patient who had not experienced the disease (control). 97, 98 In the final model, the 
variable “postnatal inhaled corticosteroids” was removed because among those who received the 
steroids dose, about 70% of the infants received their first dose beyond the time of risk 
estimation (past 21 days of age). To evaluate the fit of the final logistic regression and its 
performance, the C-statistic was used to assess discrimination, which represented the area under 
the receiver operating characteristic (ROC) curve. Discrimination is the model's ability to 
distinguish between patients who have BPD and those who do not. 
2.3 Results 
Between November 1st, 2012 and November 31st, 2018, a total of 489 infants born at 
gestational age less than 30 weeks were identified from the electronic medical records at OSF 
HealthCare Children’s Hospital. All infants in this sample survived until the day of assessment 
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for BPD at 36 weeks of postmenstrual age.  Among the infants in our cohort, 44.79% developed 
BPD. The mean birth weight for the study sample was 972.52 grams (SD: 263.41), and the 
average gestational age was 27.10 weeks (SD: 1.83) (Table 2.2). The descriptive analysis of 
sample characteristics revealed that 44.9% were females. The racial distribution among the 
sample was representative of the geographic location and the population served by the hospital 
consisting of predominantly Caucasians (68.06%), followed by Blacks (24.42%), Asians (1.88%) 
and others (5.64%). Among the mothers, 7.36% were diagnosed with chorioamnionitis during 
pregnancy, and a total of 64.21% received antenatal steroids. Additionally, 34.7% of infants 
received caffeine within 2 hours, (89.94% within 24 hours, and 95.5% within 48 hours), and 
22.49% of infants received inhaled postnatal steroids. 
Table 2.2: Descriptive statistics   
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Table 2.2 (Cont.) 
Type of ventilation 

































































































31.53 ± 16.39 
26.90 ± 11.89 
29.1 ± 13. 98 
 
25.7 ± 10.09 
21.87 ± 3.21 
22.13 ± 4.2 
 
36.95 ± 18.55 
31.07 ± 11.95 
30.96 ± 8.79 
 
38.43 ± 19.93 
34.4 ± 17.66 
38.8 ± 16.43 
 
42.3 ± 20.73 
35.46 ± 17.14 
48.61 ± 21.5 
<0.001* 
*  Statistically significant at the p-value cut-off of 0.05 
 
The existing NICHD prediction model was modified by fitting a logistic regression 
model to the new data set thereby adding new predictor variables to those already present in the 
existing model. The covariates in the final model were: (i) gestational age (ii) birth weight, (iii) 
race (iv) gender, (v) type of respiratory support (vi) highest FiO2 levels on that day (new), (vi) 
caffeine given within 24hours (for day1), within 48 hours (for day 7 and day 21) (new), and (vii) 
maternal steroids (new). Maternal diagnosis of chorioamnionitis was found to be non-significant 
and did not increase the predictive capability of the model. 
Prediction Models: 
The final model for predicting the risk of BPD on day 1 comprised of gestational age, 
birth weight, race, gender, antenatal steroids, caffeine administration within 24hours, type of 
ventilation, and maximum FiO2 levels (Table 2.3). This model had a c-statistic 0.9062. On the 
other hand, the established NICHD model had a c-statistic value of 0.8990. The difference in c-




   Table 2.3: Multinomial Logistic Regression Model for Day 1 
Variable Coefficient Standard Error p-value 
Mild BPD 
Gestational Age  -0.644 0.178 0.000*     
Birth Weight  -0.003    0.001     0.002*     
Race   0.407   0.252     0.106     
Gender   0.555    0.404      0.169     
Caffeine within 24 hrs.  -2.111     3.436     0.539     
Antenatal Steroids   0.055    0.436      0.899     
Type of Ventilation   0.286    0.123     0.020*      
Maximum FiO2   0.053    0.018      0.004*     
Constant 18.401    5.720     0.001* 
Moderate BPD 
Gestational Age  -0.500   0.177   0.005*     
Birth Weight  -0.006   0.001     0.000* 
Race   0.156   0.337      0.643     
Gender   1.142   0.377      0.002*      
Caffeine within 24 hrs. 11.877   2.945      0.000* 
Antenatal Steroids   0.578    0.579      0.318 
Type of Ventilation   0.366    0.163      0.025* 
Maximum FiO2   0.055    0.021      0.009* 
Constant   2.189    5.113      0.669 
Severe BPD 
Gestational Age  -0.417      0.169   0.014*     
Birth Weight  -0.008    0.001    0.000* 
Race  -0.070    0.460   0.878 
Gender   1.012   0.449  0.024*      
Caffeine within 24 hrs.  -1.797   6.278     0.775 
Antenatal Steroids   0.917  2.791     0.743 
Type of Ventilation   0.352  0.135     0.009* 
Maximum FiO2   0.068   0.021     0.001* 
Constant 14.314 7.111 0.044* 
 
The prediction model for the risk of BPD as assessed on day 7 included predictors of gestational 
age, birth weight, race, gender, antenatal steroids, caffeine administration within 48 hours, type 
of ventilation, and maximum FiO2 levels (Table 2.4). The improvement in c-statistic (0.9270) 






Table 2.4: Multinomial Logistic Regression Model for Day 7 
Variable Coefficient Standard Error p-value 
Mild BPD 
Gestational Age   -0.097      0.216    0.652   
Birth Weight   -0.003      0.001    0.002*     
Race    0.455      0.249      0.068     
Gender    0.635      0.363      0.080      
Caffeine within 48 hrs.   -1.646     6.501     0.800 
Antenatal Steroids    0.222      0.461      0.630 
Type of Ventilation    0.496      0.163    0.002*      
Maximum FiO2    0.232      0.050    0.000*   
Constant   -0.969   10.033    0.923     
Moderate BPD 
Gestational Age    0.100      0.231     0.666  
Birth Weight   -0.007      0.001     0.000*     
Race    0.205      0.323     0.533     
Gender    1.078      0.488    0.027*       
Caffeine within 48 hrs.  11.582      5.023     0.021*       
Antenatal Steroids    0.596     0.553     0.281 
Type of Ventilation    0.509      0.146    0.001*      
Maximum FiO2    0.250     0.051    0.000*      
Constant -17.899      9.560   0.061     
Severe BPD 
Gestational Age    0.233    0.216     0.282      
Birth Weight   -0.008     0.002    0.000*     
Race    0.005     0.427     0.991 
Gender    0.914      0.434      0.035* 
Caffeine within 48 hrs.   -2.856     7.045     0.685 
Antenatal Steroids    1.065     0.621    0.086      
Type of Ventilation    0.630    0.162     0.000*      
Maximum FiO2    0.254     0.050      0.000*      
Constant   -6.722    10.791     0.533   
 
The final prediction model for estimating BPD risk on day 21 of postnatal age of an infant 
consisted of gestational age, birth weight, race, gender, antenatal steroids, caffeine administration 
within 48 hours, type of ventilation, and maximum FiO2 levels (Table 2.5). The improvement in 
c-statistic from the established model (0.9089 to 0.9434) was statistically significant at a cut-off 





Table 2.5: Multinomial Logistic Regression Model for Day 21 
Variable Coefficient Standard Error p-value 
Mild BPD 
Gestational Age  -0.255      0.197    0.194     
Birth Weight  -0.001      0.001     0.287     
Race   0.349        0.236    0.140     
Gender   0.166      0.369    0.653     
Caffeine within 48 hrs.  -1.467      7.280     0.840 
Antenatal Steroids  -0.256      0.648     0.693      
Type of Ventilation   0.463      0.219      0.035*      
Maximum FiO2   0.330     0.073    0.000*        
Constant  -0.091    8.987     0.992     
Moderate BPD 
Gestational Age    0.202       0.251     0.420     
Birth Weight  -0.004      0.002     0.018*     
Race    0.218      0.380     0.567     
Gender    0.483      0.512     0.345     
Caffeine within 48 hrs.  11.695      3.216     0.000*      
Antenatal Steroids    0.031      0.673     0.963 
Type of Ventilation    0.769      0.234     0.001*      
Maximum FiO2    0.382      0.078  0.000*      
Constant -26.339      7.937     0.001* 
Severe BPD 
Gestational Age    0.338      0.263      0.198     
Birth Weight   -0.056      0.002    0.001*     
Race    0.037      0.489   0.935     
Gender    0.290      0.572   0.613     
Caffeine within 48 hrs.   -2.780      1.995    0.018* 
Antenatal Steroids    0.191      0.805  0.812 
Type of Ventilation    0.670   0.266  0.012*      
Maximum FiO2    0.414      0.081     0.000*      
Constant -15.203    10.676    0.154 
 
Discrimination analysis: 
The c-statistic value for the newly fitted model was higher than the existing NICHD model 









Table 2.6: C-statistic from the NICHD model and the current model on Days 1, 7, and 21 
 c-statistics for NICHD 
model 
c-statistic for the 
modified model 
P-values 
Day 1 0.8990  0.9062  0.6998 
Day 7 0.9136  0.9270 0.0067* 
Day 21 0.9089 0.9434 <0.0001* 
*  Statistically significant at the p-value cut-off of 0.05 
 
Administration of caffeine was a significant predictor of severity of BPD on day 7 and 
day 21. Thus, the timing was important. Infants who were given caffeine within 48 hours of birth 
were less likely to develop severe BPD on day 7 (coefficient= -2.63; p-value< 0.01) and day21 
(coefficient= -2.89; p-value< 0.01). However, caffeine administered within 24 hours of birth did 
not have a statistically significant effect on the prediction of BPD on day 1. The c-statistic 
improved on all three days of risk estimation with the addition of caffeine into the model.  
Administration of maternal corticosteroids was not statistically significant in our model. 
However, it contributed to an increase in the c-statistic value (day 1: 0.45%; day 7: 0.14%; and 
day 21: 0.1%).  
2.4 Discussion 
The use of non-invasive ventilation to support very low birth weight infants has been 
predominantly increasing over the last decade. In this project, a new BPD prediction model was 
developed in a cohort where non-invasive ventilation was the primary choice of ventilatory 
support. The NICHD model was chosen as the base model for our study because this is the only 
BPD prediction model which (i) was developed on a large multicenter population-based cohort 
and (ii) that performed best in discrimination and calibration analysis during an external 
validation study of all existing predictive models.95 Our novel findings revealed that the addition 
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of caffeine administration and maternal corticosteroid therapy, as well as the use of maximum 
FiO2 levels instead of mean FiO2 levels significantly improved the prediction of risk of 
bronchopulmonary dysplasia. The c-statistic of the prediction model on a postnatal Day 1 
improved from 0.8990 to 0.9062, on Day 7 from 0.9136 to 0.9270, and on Day 21 from 0.9089 
to 0.9434. Our model is more reflective of what currently occurs in the clinical arena. 
Early administration of caffeine (within 48 hours of birth) is now being recommended for 
infants who are less than 1500 grams at birth to reduce the need and duration of mechanical 
ventilation and ultimately decrease the risk of bronchopulmonary dysplasia.63, 99 Hence, those 
infants receiving caffeine early are (i) less likely to be mechanically ventilated (if on early non-
invasive ventilation), or (ii) more likely to be extubated sooner (if on early invasive ventilation), 
thereby reducing the risk of developing BPD. Caffeine administered within 48 hours of birth, in 
combination with the type of ventilation an infant receives is one of the critical predictors of 
BPD.  
Our findings are in alignment with other large-scale studies such as the Caffeine for 
Apnea of Prematurity (CAP) trial, a randomized trial conducted from 1999 to 2004. In the CAP 
trial, caffeine significantly reduced the frequency of bronchopulmonary dysplasia among infants 
assigned to the treatment group (caffeine) compared to the placebo group (adjusted odds ratio, 
0.63; 95 percent confidence interval, 0.52 to 0.76; P<0.001).62 Similar findings were reported in 
a retrospective data analysis from the Alere Neonatal Database for infants weighing ≤1250 g 
where early caffeine use was associated with a reduction in BPD (OR 0.69, 95% CI 0.58-0.82, 
p < 0.001).100 A multicenter prospective study conducted by Borszewska-Kornacka and 
colleagues revealed no differences in the severity of BPD with caffeine administered within 24 
hours vs caffeine administered within 48 hours of birth, despite the reduced need and duration of 
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invasive ventilation.101 The groups of comparison were caffeine administered within 24 hours 
and within 48 hours. However, our comparison groups were infants who received caffeine within 
48 hours and those who received caffeine after 48 hours.  
One advantage of our study is that maximum FiO2 levels on the day of risk estimation 
were included in our model instead of mean FiO2 levels. Exposure to high oxygen levels causes 
tissue injury through the formation of reactive oxygen intermediates and peroxidation of 
membrane lipids.102 Premature infants, who have severely reduced antioxidant defenses, are 
particularly sensitive to the toxic effects of oxygen. We expected that maximum FiO2 has a 
better predictive value compared to mean FiO2 levels which may not adequately reflect the 
extent of exposure to supplemental oxygen in premature infants, thereby contributing to the 
development of chronic lung disease (bronchopulmonary dysplasia). Six previous prediction 
models have used maximum FiO2 as an independent predictor of BPD.70, 74, 75, 77, 79, 86 The value 
of maximum FiO2 itself was a significant predictor of BPD in two of these models.79, 86 Fowlie 
and colleagues modified the maximum FiO2 values to maximum appropriate FiO275, which was 
defined as that associated with a simultaneous arterial or transcutaneous oxygen tension of 6.7-
10.7 kPa or an arterial hemoglobin oxygen saturation of 88-95%. The maximum appropriate 
FiO2 was one of the significant predictors of BPD. Palta et al. reported a composite lung 
function score as a predictor of BPD (p-value 0.002).77 This composite score was calculated 
using peak inspiratory pressure, maximum FiO2, and PaO2. Cuhna et al. used maximum FiO2 as 
a categorical predictor with two categories (<60% and ≥60%), and this variable was statistically 
significant in the multivariate logistic regression model (p-value 0.003).74 
Our study had notable limitations. First, the development cohort was drawn from a single 
center thus raising the concerns of external validity and generalizability of the prediction model 
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in a different setting. This has also resulted in underrepresentation of certain racial-ethnic groups 
in our cohort, consisting predominantly of Caucasians. Second, we were unable to study the 
effect of surfactant therapy in the prediction model because that variable was not available in our 
dataset. Similar to the NICHD study cohort, the use of surfactant is assumed to be prevalent in 
all very low birth infants (including those who develop and those who do not develop BPD). 
In summary, our study supports the inclusion of timing of caffeine administration, use of 
antenatal steroids, and measures of highest FiO2 levels, in addition to the existing factors of 
gestational age, birth weight, gender, race, and type of ventilation in the model in order to 
increase the prediction accuracy of BPD. In the future, a large population-based study will be 
necessary to confirm the findings of our study and validate our new BPD model. With the 
changing management approaches to the care of very low birth weight infants, specifically the 
transition to non-invasive ventilatory support and early administration of caffeine, there is a 
necessity to update the prediction model accordingly. The prediction model should reflect 
improvements/decisions in clinical treatment advances. This will enable clinicians and parents to 
make more optimal decisions on treatment options such as postnatal corticosteroids or inhaled 
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CHAPTER 3: Serum Eosinophil Cation Protein and Asthma in Children from 
Infancy to 5 Years of Age: A Systematic Review and Meta-Analysis 
3.1 Introduction 
Overview of Childhood Asthma 
Asthma is the most common chronic illness among children and adolescents in the United 
States. More than 6 million children under 18 years of age (8.4% of all children) are diagnosed 
with asthma in the US. Among them, 4.7% (935,000) are children of age 0-4 years, and 9.8% are 
children aged 5-14 years.1 Childhood asthma is the third‐ranking cause of hospitalizations in 
children and accounts for approximately 175,000 annual hospitalizations.2 Every year, 1 in 6 
children with asthma visits the Emergency Department at least once, and 1 in 20 children are 
hospitalized for asthma.1  
The economic costs of asthma have been ranked as the most significant among all chronic 
diseases due to relatively high levels of hospitalization, healthcare service uptake, and the use of 
pharmacological treatments associated with it.3 According to the American Lung Association, the 
total annual cost of asthma is approximately $56 billion a year. The yearly direct health care cost 
accounts for roughly $50.1 billion while the indirect costs from parents’ loss of pay account for 
$5.9 billion a year.4 
Asthma is characterized by episodes of cough, wheezing, and shortness of breath; 
reversible airflow limitation; and bronchial hyperresponsiveness.5 Bronchial hyperresponsiveness 
is defined as the narrowing of the airways as a response to a variety of stimuli, such as allergens 
and nonspecific triggers and infections.6 The asthma episodes are spontaneous and are often 
reversible through proper treatment. The diagnosis and monitoring of childhood asthma remain 
challenging for physicians and epidemiologists because of the absence of a standard definition.7 
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Children defined as asthmatics have an ongoing chronic inflammatory process that results in 
airway alterations and loss of lung function in early childhood, which extends to varying degrees 
into adulthood.8  
Pathophysiology of Childhood Asthma 
Asthma occurs due to the interaction between environmental and genetic factors that result 
in airway inflammation. This inflammation limits the airflow and leads to structural and functional 
changes in the airway such as bronchoconstriction, airway remodeling, mucosal edema, and mucus 
plugs which further interfere with the airflow.9 
In asthma, bronchoconstriction is the dominant event that results in clinical symptoms.10 Airway 
remodeling alters lung function and results in permanent structural changes causing airflow 
limitation. The structural changes include thickening of sub-basement membrane, subepithelial 
fibrosis, airway smooth muscle hypertrophy and hyperplasia, mucous gland hyperplasia and 
hypersecretion. These changes, if untreated, increase airflow obstruction and reduce airway 
responsiveness to treatment.11 Figure 3.1 provides an overview of the pathophysiology of asthma. 
Figure 3.1: Pathophysiology of Asthma 
 













Diagnosis of Asthma  
There is no gold standard test to diagnose childhood asthma, and it remains a clinical 
diagnosis based on a characteristic pattern of symptoms and signs in the absence of an alternative 
explanation.12 Airflow limitation or reversibility using spirometry, and related techniques are the 
surrogate measures that are used primarily in the assessment of childhood asthma. 
Diagnosing asthma in preschool children is difficult and often results in undertreatment of 
asthmatics and overtreatment of transient wheezers.3 Use of spirometry and lung function tests are 
too invasive for routine use in young children. The inability to obtain reliable pulmonary function 
tests in children below the age of 6 years, makes the diagnosis even more challenging.13 
Furthermore, the expected normal values for bronchial reactivity in infancy are unknown.14 
Therefore, a correct, timely diagnosis is the key to effectively treating asthma.  
Serum ECP as an inflammatory marker 
Serum eosinophil cationic protein (sECP) is the most widely characterized and researched 
inflammatory marker in asthma.15 Measuring sECP levels could be a reliable non-invasive method 
to measure airway inflammation and may have a significant impact on the diagnosis and 
management of asthma in young children.16 During an acute asthma episode, eosinophils are 
recruited from the bone marrow into the airways.17 ECP is one of the cytotoxic granule-derived 
proteins released from activated eosinophils, and it can be identified in sputum, bronchoalveolar 
lavage fluid, saliva, and serum of asthmatic patients.18 The unique feature of sECP levels in asthma 
is that it correlates with inflammation and asthma severity, with no correlation with bronchial 




The aim of this study is to conduct a systematic review and meta-analysis to evaluate the efficacy 
of an airway inflammatory marker, serum eosinophilic protein (ECP), in diagnosing asthma among 
children up to 5 years of age. 
Hypothesis 
An early asthma diagnosis among children younger than five years is possible using non-
invasive measurements of serum eosinophilic cation protein, as a biomarker of airway 
inflammation. 
(The manuscript for this project is currently under review at the Allergy Journal and a copy of 
the manuscript submission is provided after this section.) 
3.2 Methods 
A systematic literature search of PubMed/Medline, EMBASE, and Web of Science core 
collection databases was performed for studies published until September 2018, using the search 
terms, childhood asthma, pediatric asthma, asthma (MeSH), child (MeSH), serum ECP, 
Eosinophil Cationic Protein (MeSH), Eosinophil Granule Proteins (MeSH), and inflammatory 
markers. A detailed search strategy was reported in a flowchart of the literature search and 
selection criteria (Figure S1). Additionally, clinicaltrials.gov database was used to identify 
ongoing clinical trials on this topic and obtain relevant data.  
Eligibility Criteria 
The following inclusion criteria were used for the current systematic review: (1) peer-
reviewed articles written in English; (2) asthma as the index disease; (3) study sample up to 5 years 
of age; and (4) serum ECP used as the biological marker. Asthma as the index disease was 
determined based on the definitions of i) at least three episodes of wheezy bronchitis,11, 13, 16-18 ii) 
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an episodic cough and wheeze responsive to β2 agonists, persisting or recurring for at least six 
months12, or (iii) a methacholine challenge test.15  
Data extraction 
A standardized data extraction form was used to obtain information regarding the 
methodology and results from the studies identified for this manuscript: author, publication year, 
study hypothesis, study design, sample size, characteristics of study and comparison groups, sECP 
measures, conclusions, and disadvantages of the studies (Appendix-2). 
Assessment of Study Quality 
The quality of each study in the systematic review was assessed using the QUADAS-2 
criteria tabulated in Table 3.1. QUADAS-2 is the recommended tool to evaluate the risk of bias 
and applicability of diagnostic accuracy studies within systematic reviews. This criterion consists 
of four key domains: (i) patient selection, (ii) index test, (iii) reference standard, (iv) flow and 
timing. 
Table 3.1: QUADAS-2: Quality assessment criteria for studies included in the systematic review 
Research question 
                        Was the research question or objective in the paper clearly stated? 
Study population 
                        Was the study population specified and defined? 
Selection bias 
                        Are the individuals that are selected to participate in the study likely                
                        to be a representative of the target population? 
Inclusion and exclusion criteria 
                        Were inclusion and exclusion criteria for participating in the study pre‐  
                            specified and applied uniformly to all the participants? 
Measurement of exposure 
                        Were the exposure measures clearly defined, valid, reliable, and  
                         implemented consistently across all study participants? 
Index test 
                        Were the s-ECP results interpreted without knowledge of the results  
                         of the reference standard? 
Outcome measures 





A meta-analysis was performed to estimate the pooled effect size of serum ECP as a 
diagnostic test for asthma in children less than 5 years of age. Hierarchical summary receiver 
operating characteristic curves (HSROC) were used to summarize the overall test performance 
from the meta-analysis. The reported sensitivities and specificities from the studies were 
summarized using diagnostic odds ratio (dOR). The dOR is a measure of the accuracy of the test 
data that combines sensitivity and specificity into a single value ranging from zero to infinity. 
Higher values of dOR indicate better discriminatory performance of the test.  
The heterogeneity of the results across studies was evaluated using the I2 statistical 
parameter. The value of I2 was >50% indicating that a large percentage of total variation across 
studies was due to heterogeneity rather than chance. Given that the heterogeneity was large, the 
results of the different studies were pooled using a random-effects model. 
3.3 Results 
A detailed study selection flow chart is shown in Figure 3.2. A total of 799 articles were 
identified from database searches after removing the duplicates. Based on the title and abstract, 
762 studies were eliminated. After reviewing 37 full-text articles against study eligibility criteria, 
eight studies fulfilled the study inclusion criteria and were included in the systematic review.11-18 







Figure 3.2: A PRISMA flow diagram illustrating the search strategy for the review 
 
 The selected studies were published between 1994 and 2004 and originated from eight 
different countries, consisting of one retrospective 5, four prospective,3, 4, 8, 9 and three cross-
sectional studies.6, 7, 10 There was a high degree of clinical heterogeneity between studies 
primarily related to the definition of asthma, type of patients, use of asthma treatment, and timing 
of sECP assessment. (Table 3.2).
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Table 3.2: Summary of studies investigating the role of serum eosinophil cationic protein in diagnosing childhood asthma 
Author Hypothesis Study Design Study Sample Comparison 
Group 









inflammation is less 
clear in early 
childhood than later 




atopy, and serum 
eosinophil cationic 












for asthma and 
atopy 
 
Mean age of 
this group was 
71.0 months 
(SD 2.4), and 








birth and 1 and 




at 1, 2, 3, and 6 








to 4 common 
allergens (dust 
mite, ryegrass, 






No controls Asthma was defined as 
wheezing or cough 
without a cold in the 
preceding 12 months 
with a physician’s 
diagnosis, and ever and 
current use of reliever or 
preventive medication 
Serum ECP levels.   
 
Detailed clinical history 
and examination, lung 
function testing, 
methacholine challenge, 
and skin prick testing to 
4 common allergens 
were undertaken. 
 
Lung function was 
measured by using 
standard spirometry 
(Model 6100; Welch 
Allyn, Skaneateles 
Falls, NY) 
A total of 191 
(19.7%) children had 
current asthma, with 
114 (59.7%) of these 
being atopic. The 
mean serum ECP 
level for the entire 
group was 18.0 µg/L 
(range, 2.0-146.0 
µg/L), with no 
difference between 
male and female 
patients. Serum ECP 
was higher in atopic 
children (20.5 +/- 
18.4), those with 
asthma (22.4 +/- 
19.6), and those with 
asthma and atopy 
(26.6 +/- 22.4; all P 
< .001 compared 
with children with 
no asthma or atopy 
[16.1 +/- 15.9]). 
Serum ECP levels 
were highest in 
children with severe 
asthma ( P < .001), 
especially in those 
with concurrent 
atopy. Severity of 
atopy, judged on the 
basis of wheal size 
or combining wheal 
size and the number 
of positive skin tests, 






not associated with 
increased serum 
ECP levels. 
The higher serum 
ECP levels seen in 
6-year-old children 
with current asthma 
and more severe 




important in driving 
this clinical 
phenotype and that 
this might represent 










whether, in infants 
experiencing their 
first episode of 
wheezing, 
eosinophil 
activation is present 














age, 7 months; 
range, 4 to 9 
months; 23 
boys and 10 






age, 8 months; 
range, 3 to 12 
months; 9 boys 















age, 7 months; 
range, 2 to 13 
months; 7 
boys and 5 
girls) 
 
Asthma was defined as 
three or more episodes of 
wheezy bronchitis in the 
past year with other 
conditions excluded and 
responsive to β2 agonists. 
Parents of the infants 
completed a 
questionnaire about 
their own history of 
respiratory illness, 
atopy, and smoking 
habits 
 
Daily diary, which 
recorded symptoms 
as wheeze, cough, 
and breathlessness. 
 
Blood samples were 
drawn and processed 
according to the 
manufacturers' 
recommendations. 
ECP in serum was 
determined by means 






Sweden) in duplicate. 
 
In wheezing infants, 
eosinophil counts 
were not different 
from those in 
children with colds 
without wheezing or 
healthy control 











were not correlated in 
patients with wheezy 
bronchitis.  
 
Wheezing infants had 
higher median serum 
ECP levels (13.4 
µg/L) than children 
with nonwheezy 
respiratory tract 
infection (7.6 µg/L, p 
< 0.005) or healthy 
subjects (7.1 
µg/L, p < 0.005). In 
addition, wheezing 
infants (n = 13) with 
serum ECP 
concentrations 
greater than 20 µg/L 
were more likely to 
have asthma within 1 
year than patients 
with ECP levels less 
than 20µg/L (odds 




measured by serum 
ECP is present in 
infants with their first 
episode of wheezing 
illness, especially in 
those infants in 
whom asthma 
subsequently 
develops within 1 
year. These data may 
indicate a predictive 
value of serum ECP 
measurements in 
children with 
wheezing to identify 
those patients in 
whom infantile 
asthma is developing. 
These findings 
probably also 
indicate that serum 
ECP may be used to 
identify the children 








Table 3.2 (Cont.) 





To examine their 
possible predictive 
value for the 
development of 
asthma, the serum 
concentration of 
eosinophil cationic 
protein (ECP) and 






25 children aged 
1-17 months 










defined as 3 or 
more episodes of 
wheezing, with 
at least one of  
the episodes in 
the last year.  
The remaining 
15 children had 
experienced only 
1 or 2 episodes 
of wheezing, and 
all of these 
children had 
been wheeze 










(mean age 62  
months; range 
13 to 86 
months) 
Asthma was defined as 
three or more episodes of 
wheezing with no signs 
of other conditions, with 
at least one of the 
episodes during the last 
year. 
sECP and total 
eosinophil count 
 





After an average of  3 
years, the parents of 





asthma. They were 




chronic cough and if 
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a clinical history 
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or more episodes 
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winter) or if they 
had cough or 
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Having a clinical history 
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as three or more episodes 
of wheezing before visit 
1. Persistant wheezers at 
the time of secoond visit 
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who had at least one 
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they had cough or 
dyspneoa with exercise. 
Serum concentrations 
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cationic protein were 
measured 
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group 1 than in 
group 2: 
29.63 (5.16) v 14.42 
(2.77) μg/l, p < 
0.01. 
 
At visit 2, there was 
a significant 
difference between 





1, 35.31 (7.73) μg/l 
v group 2, 17.02 
(2.38) μg/ 
l; p < 0.01) 
Eosinophilic 
inflammation 
is present from the 
onset of the disease 
in the group of 
wheezing young 
children who 
are going to continue 
with wheezing 
episodes 
at age 5–6 years. 
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Quality of evidence: Most of the included studies had a low4, 8-10 or medium risk3, 5 of bias. A 
high risk of bias was noted primarily in: i) the interpretation of index test results without the 
knowledge of the reference standard results, and ii) pre-specification of threshold values.5-7 The 
details of the risk of bias assessment using the QUADAS-2 tool are summarized in Figure 3.3. 
Figure 3.3: Summary of risk of bias assessment using the QUADAS-2 tool (n=8) 
 
Pooled Sensitivity Analysis: In four individual studies, calculated sensitivities varied from 0.70 
to 0.92 and specificities from 0.48 to 0.95.  Pooled sensitivity was 0.79 (95% CI: 0.66 - 0.88), 
pooled specificity was 0.79 (95% CI: 0.54 - 0.92), and the pooled diagnostic odds ratio (dOR) 
was 14.73 (95% CI: 3.58 - 60.58) (Figure 3.4). The area under the hierarchical summary receiver 
operating characteristic (HSROC) estimating the discriminating accuracy of serum ECP was 0.81 
(95% CI: 0.78- 0.85) with a considerable heterogeneity of the dOR (Q=4.3, df=2 (p=0.05), I2= 
54%) (Figure 3.5). P-values for the differences in DOR and threshold parameter estimates was 
not statistically significant. The 95% confidence region for the point that summarized the overall 
test performance included studies was almost identical to the 95% prediction region. 
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Figure 3.4: Sensitivity and Specificity in included studies 
 
 




Serum ECP levels: Data from three studies were pooled to assess the difference in sECP levels 
between asthmatic and non-asthmatic children.4, 5, 9 The sECP levels were not significantly 
different among asthmatic children 5 years or younger (as determined by reference tests) 
compared to non-asthmatic children in the same age group (mean difference 11.25µg/dl; 95% 
CI: 4.97 - 27.46; p=0.17) (Figure 3.6). The total sample size for asthmatic children and non-










To our knowledge, this is the first study to determine the role of sECP in the diagnosis of 
childhood asthma in young children less than five years of age. The pathophysiology and 
recommended treatment approaches of asthma are different for this age group because the 
airways and lungs are more vulnerable to permanent damage from repeated inflammation at such 
a young age. Hence, determining the role of sECP in this specific population would contribute to 
clinical decision-making of this vulnerable population. 
Five out of eight studies demonstrated the usefulness of sECP levels in diagnosing childhood 
asthma3, 4, 6, 9, 10; however, when these studies were combined in a meta-analysis, the results were 
non-significant. Thus, overall, this review found limited evidence that measuring sECP levels 
during early childhood distinguish the children with asthma from children with virus-associated 
wheeze. Several factors prevented a definitive conclusion from the systematic review and meta-
analysis. Not all studies reported quantitative measures of sECP levels or the necessary 
information to calculate sensitivities and specificities. Furthermore, the studies were very 
heterogeneous, had very small sample sizes, and methodologically were not robust, restricting 
the reliability and applicability of these results. The diagnostic criteria for childhood asthma were 
not standardized across the studies and therefore resulted in variability in outcome measures. 
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Finally, none of the studies adjusted for potential confounders including circadian rhythm, age, 
smoking, and seasonal variations primarily related to allergic reactions. 
The existing evidence is insufficient to support or refute the role of sECP in diagnosing 
asthma among children ≤ 5 years. In the future, researchers should design a multicentric 
population-based prospective study with longer follow-up periods and standardized methods to 
collect and measure sECP levels, taking storage time and ambient temperature into account. 
Additionally, sECP may possibly be a valuable biomarker if measured in a larger group of 
younger asthmatic patients, stratified by age (0-2 years), during the critical time for lung 
development. Finally, the role of sECP should be measured in conjunction with other biomarkers 




1. Centers for Disease Control and Prevention. Asthma. Most Recent Asthma State or Territory 
Data. Updated May 2018. Available from 
https://www.cdc.gov/asthma/most_recent_data_states.htm. 
 
2. Klonoff‐Cohen H, Polavarapu M . Eosinophil protein X  and childhood asthma: A systematic 
review and meta‐analysis. Immunity, Inflammation and Disease. 2016;4(2):114-134. 
doi:10.1002/iid3.104. 
 
3. Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United 
States, 2008-2013. Annals of The American Thoracic Society [serial online]. n.d.;15(3):348-
356. 
 




5. Spahn J, Covar R. Clinical assessment of asthma progression in children and adults. The 
Journal Of Allergy And Clinical Immunology [serial online]. March 2008;121(3):548-557. 
 
6. Van Aalderen WM. Childhood Asthma: Diagnosis and Treatment. Scientifica. 2012; 
2012:674204. doi:10.6064/2012/674204. 
 
7. Cave A, Atkinson L. Asthma in Preschool Children: A Review of the Diagnostic Challenges. 
Journal of The American Board Of Family Medicine [serial online]. n.d.;27(4):538-548.  
 
8. Gelfand E. Pediatric asthma: A different disease. Proceedings of The American Thoracic 
Society [serial online]. May 1, 2009;6(3):278-282.  
 
9. Sharma G, Gupta P. What is the role of airway inflammation in the pathophysiology of 




10. Expert Panel Report 3. [Bethesda, Md.]: National Institutes of Health, National Heart, Lung, 





11. Joseph-Bowen J, De Klerk N, Holt PG, Sly PD. Relationship of asthma, atopy, and bronchial 
responsiveness to serum eosinophil cationic proteins in early childhood. Journal of Allergy 
and Clinical Immunology. 114(5):1040-1045. doi:10.1016/j.jaci.2004.07.051. 
 
12. Koller DY, Wojnarowski C, Herkner KR, et al. High levels of eosinophil cationic protein in 
wheezing infants predict the development of asthma. The Journal of Allergy and Clinical 
Immunology. 1997;99(6 Pt 1):752-756. 
 
13. Øymar K, Bjerknes R. Is serum eosinophil cationic protein in bronchiolitis a predictor of 
asthma? Pediatric Allergy and Immunology. 9(4):204-207. doi:10.1111/j.1399-
3038.1998.tb00374.x. 
 
14. Lodrup Carlsen KC, Halvorsen R, Ahlstedt S, Carlsen K-H. Eosinophil cationic protein and 
tidal flow volume loops in children 0-2 years of age. European Respiratory Journal. 
8(7):1148-1154. doi:10.1183/09031936.95.08071148. 
 
15. Reichenbach J, Jarisch A, Khan S, Hömberg M, Bez C, Zielen S. Serum ECP levels and 
methacholine challenge in infants with recurrent wheezing. Annals of Allergy, Asthma and 
Immunology. 89(5):498-502. doi:10.1016/S1081-1206(10)62088-1. 
 
16. Sigurs N, Bjarnason R, Sigurbergsson F. Eosinophil cationic protein in nasal secretion and in 
serum and myeloperoxidase in serum in respiratory syncytial virus bronchiolitis: Relation to 
asthma and atopy. Acta Paediatr Int J Paediatr 1994;83(11):1151-1155. 
 
17. Villa JR, García G, Rueda S, Nogales A. Serum eosinophilic cationic protein may predict 
clinical course of wheezing in young children. Archives of Disease in Childhood. 78(5):448-
452. doi:10.1136/adc.78.5.448. 
 
18. Yu J, Yoo Y, Kim DK, Kang H, Koh YY. Bronchial responsiveness and serum eosinophil 
cationic protein levels in preschool children with recurrent wheezing. Annals of Allergy, 
Asthma and Immunology. 94(6):686-692. doi:10.1016/S1081-1206(10)61329-4. 
57 
 
3.6 Submitted Manuscript 
Asthma is the most common chronic illness among children and adolescents in the United 
States. Childhood asthma is the third cause of hospitalizations in children. Every year, 1 in 6 
children with asthma visits the emergency department at least once, and 1 in 20 children are 
hospitalized for asthma.1  
The diagnosis of childhood asthma remains challenging for physicians because of the 
absence of a standard definition and gold standard test. Rather, it consists of a clinical diagnosis 
based on a characteristic pattern of symptoms and signs in the absence of an alternative 
explanation. Use of spirometry and lung function tests are too invasive for use in young children. 
The inability to obtain reliable pulmonary function tests in children below the age of 6 years, 
makes the diagnosis even more challenging.2 Furthermore, the expected normal values for 
bronchial reactivity in infancy are unknown. Performing bronchoalveolar lavage and determining 
exhaled nitric oxide in children under five years of age is difficult, and thus, not useful as routine 
diagnostic tools in this age group. 
For children who have recurrent wheezing and are later diagnosed with asthma, it is 
necessary to develop a noninvasive technique to quantify the inflammatory process. Serum 
eosinophil cationic protein (sECP) is the most widely characterized and researched inflammatory 
marker in asthma. Serum ECP levels could serve as a reliable non-invasive method to measure 
airway inflammation and confirm the diagnosis of asthma in young children. The unique feature 
of sECP levels in asthma is that it correlates with inflammation and asthma severity, with no 
correlation with bronchial hyperreactivity. The correlation with asthma severity has been 
measured by symptom score and spirometry. 
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The aim of this study is to conduct a systematic review and meta-analysis to evaluate the 
efficacy of an airway inflammatory marker, sECP, in accurately diagnosing asthma among 
children < 5 years of age.  
Methods 
A systematic literature search of PubMed/Medline, EMBASE, and Web of Science core 
collection databases was performed for studies published until September 2018, using the search 
terms, childhood asthma, pediatric asthma, asthma (MeSH), child (MeSH), serum ECP, 
Eosinophil Cationic Protein (MeSH), Eosinophil Granule Proteins (MeSH), and inflammatory 
markers. A detailed search strategy was reported in a flowchart of the literature search and 
selection criteria (Figure S1). Additionally, clinicaltrials.gov database was used to identify 
ongoing clinical trials on this topic and obtain relevant data.  
Using the title and abstract, the literature search results were screened against the study 
selection criteria to identify potentially relevant studies for full review. A full-text review was 
conducted on the remaining articles to determine their eligibility for inclusion in the study. 
Eligibility Criteria 
The following inclusion criteria were used for the current systematic review: (1) peer-
reviewed articles written in English; (2) asthma as the index disease; (3) study sample up to 5 years 
of age; and (4) serum ECP used as the biological marker. Asthma as the index disease was 
determined based on the definitions of i) at least three episodes of wheezy bronchitis,26, 28, 31-33 ii) 
an episodic cough and wheeze responsive to β2 agonists, persisting or recurring for at least six 






The following data were extracted from the studies identified for this manuscript: author, 
publication year, study hypothesis, study design, sample size, characteristics of study and 
comparison groups, sECP measures, conclusions, and disadvantages of the studies (Appendix-2). 
Assessment of Study Quality 
The quality of each study in the systematic review was assessed using the criteria 
tabulated in the table below (Table 3.1) using the QUADAS 2 scale.  
Results 
The selected studies were published between 1994 and 2004 and originated from eight different 
countries, consisting of one retrospective 5, four prospective,3, 4, 8, 9 and three cross-sectional 
studies.6, 7, 10 There was a high degree of clinical heterogeneity between studies primarily related 
to the definition of asthma, type of patients, use of asthma treatment, and timing of sECP 
assessment. (Table 3.2). 
Quality of evidence: Most of the included studies had a low4, 8-10 or medium risk3, 5 of bias. A 
high risk of bias was noted primarily in: i) the interpretation of index test results without the 
knowledge of the reference standard results, and ii) pre-specification of threshold values.5-7 The 
details of the risk of bias assessment using the QUADAS-2 tool are summarized in Figure 3.3. 
Pooled Sensitivity Analysis: In four individual studies, calculated sensitivities varied from 0.70 
to 0.92 and specificities from 0.48 to 0.95.  Pooled sensitivity was 0.79 (95% CI: 0.66 - 0.88), 
pooled specificity was 0.79 (95% CI: 0.54 - 0.92), and the pooled diagnostic odds ratio (dOR) 
was 14.73 (95% CI: 3.58 - 60.58) (Figure 3.4). The area under the curve was 0.81 (95% CI: 0.78 
- 0.85) with considerable heterogeneity of the dOR (Q=4.3, df=2 (p=0.05), I2= 54%). 
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Serum ECP levels: Data from three studies were pooled to assess the difference in sECP levels 
between asthmatic and non-asthmatic children.4, 5, 9 The sECP levels were not significantly 
different among asthmatic children 5 years or younger (as determined by reference tests) 
compared to non-asthmatic children in the same age group (mean difference 11.25µg/dl; 95% 
CI: 4.97 - 27.46; p=0.17) (Figure S1). The total sample size for asthmatic children and non-
asthmatic children were very small, consisting of 61 asthmatics and 51 non-asthmatics, 
respectively.  
Discussion 
To our knowledge, this is the first study to determine the role of sECP in the diagnosis of 
childhood asthma in young children less than five years of age. The pathophysiology and 
recommended treatment approaches of asthma are different for this age group because the 
airways and lungs are more vulnerable to permanent damage from repeated inflammation at such 
a young age. Hence, determining the role of sECP in this specific population would contribute to 
clinical decision-making of this vulnerable population. 
Five out of eight studies demonstrated the usefulness of sECP levels in diagnosing childhood 
asthma3, 4, 6, 9, 10; however, when these studies were combined in a meta-analysis, the results were 
non-significant. Thus, overall, this review found limited evidence that measuring sECP levels 
during early childhood distinguish the children with asthma from children with virus-associated 
wheeze. Several factors prevented a definitive conclusion from the systematic review and meta-
analysis. Not all studies reported quantitative measures of sECP levels or the necessary 
information to calculate sensitivities and specificities. Furthermore, the studies were very 
heterogeneous, had very small sample sizes, and methodologically were not robust, restricting 
the reliability and applicability of these results. The diagnostic criteria for childhood asthma were 
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not standardized across the studies and therefore resulted in variability in outcome measures. 
Finally, none of the studies adjusted for potential confounders including circadian rhythm, age, 
smoking, and seasonal variations primarily related to allergic reactions. 
The existing evidence is insufficient to support or refute the role of sECP in diagnosing 
asthma among children ≤ 5 years. In the future, researchers should design a multicentric 
population-based prospective study with longer follow-up periods and standardized methods to 
collect and measure sECP levels, taking storage time and ambient temperature into account. 
Additionally, sECP may possibly be a valuable biomarker if measured in a larger group of 
younger asthmatic patients, stratified by age (0-2 years), during the critical time for lung 
development. Finally, the role of sECP should be measured in conjunction with other biomarkers 
to evaluate the diagnostic capabilities of inflammatory markers in childhood asthma. 
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CHAPTER 4: A Risk Scoring System for Sudden Infant Death Syndrome (SIDS) 
4.1 Introduction 
Sudden infant death syndrome (SIDS) is defined by the National Institute of Child Health 
and Human Development as “the sudden death of an infant under one year of age, which remains 
unexplained after a thorough case investigation, including performance of a complete autopsy, 
examination of the death scene, and review of the clinical history.”1 In 2016, there were about 
1,500 deaths due to SIDS.2 SIDS is the third leading cause of death for all infants in the United 
States from birth to one year after congenital malformations and low birth weight.  
Most SIDS deaths are typically associated with a sleep period3 with death presumed to 
have occurred during sleep itself or in the transition between sleep and waking.4 While the 
definition includes the deaths in infants up to 1 year of age, nearly 95% of SIDS deaths occur in 
the first six months of life with a peak incidence in infants aged 2-4 months.5 This age reflects the 
period when the brain is undergoing remarkable neurodevelopmental changes, especially to 
pathways and systems controlling homeostatic control.5  
The exact etiology of SIDS is unknown and a number of risk factors have been identified 
leading to these deaths in infants. Among many proposed mechanisms, SIDS infants are 
hypothesized to have defects in respiratory control resulting in altered respiratory function, 
prolonged periods of apnea, a failure of autoresuscitation, and defective arousal mechanisms.6-8 
The latest evidence for the mechanism of death in SIDS involves complex interactions between 






The incidence of SIDS 
A dramatic decrease in the incidence of SIDS has been reported since the introduction of 
safe sleep campaigns, with a 30-83% reduction in SIDS rates worldwide, and more than a 50% 
drop in the United States.10, 12 Several factors should be considered when interpreting the reason 
for this dramatic decline in SIDS rates. It is imperative to note that there has been a diagnostic shift 
in recent years, making the comparison of data across years less reliable.13 SIDS is now included 
under the common umbrella of Sudden Unexpected Infant Deaths (SUID) consisting of: (i) SIDS, 
(ii) unknown cause, and (iii) accidental suffocation and strangulation in bed.2 This shift resulted 
in a decrease in the application of SIDS as a diagnosis, with many professionals classifying cases 
into other categories. Most commonly employed terms now include “undetermined,” “unknown,” 
“unascertained” or “ill-defined,” despite the fact that cases fulfill the criteria for SIDS 14 
In addition to identifying risk factors for SIDS, the 1990s was also characterized by the 
establishment of standardized protocols for both death scene and autopsy examinations to improve 
infant death scene investigations.15 These protocols were aimed at improving diagnostic accuracy 
by providing additional information to enable more accurate determination of causes of death and 
to facilitate more meaningful comparisons of infant death rates between populations.16  
SIDS is based entirely on a diagnosis of exclusion and is a  term used when no other known 
cause of death can be determined using a process of elimination. This leads to a large window of 
interpretation, especially considering that not all SIDS cases have the same characteristics.17 A 
disease with no defined pathology is challenging to diagnose. In the past, SIDS was diagnosed 
even when the investigation did not fulfill the required definition or an autopsy was performed, 
just because no other cause of death was identified.18-20 It is estimated that an alternative diagnosis 
could have been made for up to 25% of SIDS cases or more.21, 22 
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Most importantly, there was widespread national publicity during the Back to Sleep 
Campaign about SIDS. This increased parental awareness, caused parents to be more cautious and 
watchful with their infants. An indirect message regarding breastfeeding and not smoking around 
the baby within the Sleep campaign also contributed to the drop in SIDS rates. 
Triple Risk model 
The Triple Risk Model (Figure 4.1) proposes that SIDS is not dependent on a single risk 
factor, but rather an interaction among three different conditions that are required to overlap with 
one another, suggesting that the sudden infant death is a multi-factorial disease that only occurs if 
the three conditions are present at the same time. The conditions are: (i) a vulnerable infant, (ii) a 
critical period of development and (iii) an external stressor with which the infant is unable to cope. 
According to the model, an infant is vulnerable due to a genetic or a developmental anomaly. This 
vulnerability is not evident until the infant enters a critical period of development and is exposed 
to an external stressor, altogether compromising the infant’s homeostatic system. 
Evidence supporting a Vulnerable Infant includes: 
1. Maternal and pregnancy-related factors, 
2. Neonatal abnormalities in neurological or autonomic function, 
3. Post-neonatal abnormalities in cry, cardiac and ventilatory patterns, and 
4. Subtle CNS as well as systemic abnormalities.  
The critical developmental period is specifically between two to four months following 
birth. During this time, extensive physiological changes take place in the infant’s brain that are 
crucial for homeostatic control. 
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Exogenous stressors such as overheating with excessive bedding, prone sleeping position, 
soft bedding, and co-sleeping are some of the factors that can be divided into extrinsic as well as 
intrinsic factors. They further deteriorate the infant’s homeostatic system. 
 
Figure 4.1: Triple Risk Model 
 
Reproduced from Triple Risk Model for SIDS proposed by Filiano and colleagues in 1994, highlighting the 
intrinsic, extrinsic and additional risk factors for SIDS.23 
  
 
Gender, Prematurity, Low Birth Weight: The incidence of SIDS is higher in male 
infants when compared to females at a ratio of 60 to 40 respectively.24, 25 This could be due to 
differences in genetic and biological makeup or because male infants have a higher mortality rate 
and are more susceptible to illness than females.26 Males are also prone to more disruptive sleep 
patterns.  Low birth weight, as well as prematurity, increase the risk of SIDS by fourfold due to 
the immature autonomic nervous system.27, 28 
Maternal smoking and drug use: Although prone sleeping has reduced over time, 
maternal smoking during pregnancy has continued to rise from 50% to 80%.29 Prenatal exposure 
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to maternal smoking increases the relative risk of SIDS up to fivefold. Postnatal exposure such as 
second-hand smoking also impacts an infant’s well-being.30 It has been hypothesized that nicotine 
from the maternal circulation can cross over into the fetal circulation. Nicotine binds to the 
nicotinic receptors in the fetal brain31 and alters the fetal physiology such as impaired arousability32 
and parasympathetic control of the heart rate.33 
A direct relationship between drug use and SIDS is harder to determine due to the 
confounding nature of poly-drug use coupled with smoking during pregnancy.34, 35 However, there 
is substantial evidence that shows that drug use and smoking during pregnancy result in 
prematurity along with low birth weight babies, which are known to increase the risk of SIDS.36 
Sleep Position, Bed Sharing, Soft bedding, and Over Heating: Prone sleep position 
results in additional physiological stress on the cardiorespiratory system, thereby resulting in a 14-
fold increase in the risk of SIDS.37 Suffocation, hypoxia due to oxygen deprivation, hypercarbia 
as a result of re-breathing carbon dioxide, airway obstruction, reduced arousal responses, and 
altered cardiovascular capacity are some of the factors that account for death due to prone 
sleeping.38-40 
Sharing a sleep surface could potentially cause overlaying, suffocation or overheating, thus 
increasing the risk for infant death.41 This risk is even higher when additional factors such as 
prematurity, low birth weight, intoxication, and cigarette smoking are present.42, 43  
Soft bedding and surfaces are hypothesized to result in a trough, as the surface easily 
depresses under the infant’s weight.44 As the infant is not able to free themselves from such a 
precarious situation, this results in asphyxia, suffocation or overheating.45 Kleemann et al. 
suggested that hyperthermia could play a role in SIDS due to over-bundling or covering of the face 
or head of the infant.46 
67 
 
Circumcision: The relationship between circumcision and SIDS remains unproven. The 
theory behind circumcision as a risk factor for SIDS was proposed in 2016 by Dr. Elhaik from the 
University of Sheffield, UK. According to this proposed theory, elective neonatal circumcision is 
associated with hypersensitivity to pain and decreased heart rate variability, thereby increasing the 
risk for SIDS. The infant’s ability to allosterically regulate exposure to stressors is severely 
reduced, which increases their vulnerability to premature death. This also explains the higher 
prevalence of SIDS in male compared to female infants. 
 
Hypothesis 
  If new risk factors including (breastfeeding, maternal and paternal smoking, circumcision, 
overheating, sleep position at the time of death, and routine sleep position) are added to the existing 
scoring system, then this could contribute to a more accurate prediction of which infants are at 
higher risk for succumbing to SIDS within their first year of life. 
Specific Aims 
1. To examine the seven existing SIDS risk scoring systems to determine the most common 


















Table 4.1: Odds ratios for individual risk factors from the literature 
Risk Factor Odds Ratio (95% CI) 
Mother age <25 years 1.41 (0.55 - 3.60)47 
Maternal smoking 2.25 (2.03 - 2.50)48 
Household smoke exposure 1.7 (1.2 - 2.3)49 
Maternal alcohol use 6.9 (4 - 11.9)50 
Breastfeeding 0.4 (0.28 - 0.58)51 
Low birth weight 3.3252 
Prematurity 11.67 (1.84 - 74.14)53 
Male 1.754 
African American 1.9655 
Circumcision Not available 
Prone sleep position 1.3 (1.1 - 1.5)56 
Bed sharing 2.89 (1.99 - 4.18)57 
Soft bedding 5.1 (3.1-8.3)58 
 
2. To develop a new SIDS risk scoring system to identify the cumulative effects of maternal, 
infant and environmental factors predictive of SIDS risk. In addition to the existing 
established risk factors, the new variables of breastfeeding, low birth weight (LBW), 
maternal and paternal smoking, breastfeeding duration, circumcision (potential risk factor), 
routine sleep position, maternal use of alcohol during pregnancy, maternal use of 
recreational drugs, maternal anemia during pregnancy, infants’ exposure to passive smoke 








Table 4.2: List of risk factors included during the development of SIDS risk scoring system 
Factors from existing models New risk factors for the model 
• Mothers’ age 
• Birthweight 
• Maternal smoking 
• Gender 
• Gestational age 
• Breastfeeding duration 
• Paternal smoking 
• Circumcision (potential risk factor) 
• Routine sleep position  
• Maternal use of alcohol during 
pregnancy 
• Maternal use of recreational drugs 
• Maternal anemia during pregnancy 
• Infants’ exposure to passive smoke 
 
4.2 Methods 
Study population and data collection: This study consisted of a secondary analysis of data 
from a case-control study, which was a part of the University of California Tobacco-Related 
Disease Research Program. The study sample was based on the available data from the original 
study consisting of 291 mothers of SIDS infants and 242 mothers of healthy control infants. For 
the initial data collection, the study was approved by the Human Subjects Committee at the 
University of California, San Diego. The current data analysis was conducted on a de-identified 
data set, and no additional approval or consent was obtained for this subsequent analysis.  
During data collection, cases were identified based on death certificates from five health 
departments located in the Southern California counties of San Bernardino, Riverside, San 
Diego, Orange, and Los Angeles. The diagnosis of SIDS was ascertained by autopsy reports 
based on the coroner’s offices use of the Autopsy Protocol for Sudden Unexpected Infant Death 
and Death Scene and Deputy Coroner Investigation protocols among infants (less than one year 
of age) who died between January 1st, 1989 and December 31st, 1992. A total of 200 infant cases 
(out of 291) were matched to living control infants (one control per case) on the basis of birth 
hospital, birthdate, sex, and race. The original data were obtained from a comprehensive 
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telephone interview in English/Spanish, and the information was validated using mothers’ 
(obstetric) and baby’s (pediatric) medical records. 
Selection of predictor variables: The risk factors were selected based on examination of the 
seven existing SIDS risk scoring systems to determine the additional most common risk factors 
with the highest odds ratios in literature and best biologic plausibility. A range of potential risk 
factors for SIDS were evaluated including mothers’ age at the time of childbirth, maternal and 
paternal smoking statuses during pregnancy, infants exposure to passive smoke (mother, father 
or caretaker), maternal alcohol use during pregnancy, maternal use of recreational drugs during 
pregnancy, gestational age, birth weight, breastfeeding duration, routine sleep position, and co-
sleeping habits. An additional variable of circumcision, which has recently been proposed as a 
potential risk factor, was included to perform an exploratory analysis of its epidemiological 
association with SIDS. Gender was not included as one of the predictor variables because the 
sample consisted of 200 cases matched to controls on the basis of both gender and race. 
Statistical Analysis: Descriptive statistics were used to characterize the cases and controls using 
mean and standard deviation for continuous variables, and percentages for categorical variables. 
All analyses were performed using STATA 15.0 statistical software. The missing data was 
handled in STATA software by dropping the observations. Less than 5% (a maximum of 3.5%) 
of observations in individual variables were with missing data. 
A multivariate logistic regression model was developed to predict the risk of SIDS among infants 
less than one year of age. The first step of the model development was to examine the 
relationship between SIDS and each risk factor using the study data. The variables with p-values 
less than .30 were entered into the multivariate model. A stepwise forward selection logistic 
regression model was used to retain variables with P< .05. In the final model, the variable 
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“maternal alcohol intake during pregnancy” was removed because of its inverse relationship with 
the outcome measure (i.e., the SIDS rates were lower among mothers who consumed alcohol 
during pregnancy). This could possibly because of the similar consumption rates among both 
cases and controls. Given the known negative health outcomes among infants born to mothers 
drinking while pregnant, this result appeared to be an artifact of the study data set and the 
research team agreed to remove it from the final model. To evaluate the fit of the final logistic 
regression and its performance, the C-statistic was used to assess discrimination, which 
represented the area under the receiver operating characteristic (ROC) curve. Bootstrap methods 
were used to obtain a bias-corrected confidence interval for the calculated C-statistic. Calibration 
was measured statistically using the Hosmer-Lemeshow test. 
Derivation of SIDS risk score: The risk score was developed based on the final logistic 
regression model using the regression coefficients as described by Mehta et. al.59 First, the 
continuous variables (e.g., maternal age at the time of birth, breastfeeding duration) were broken 
into categories based on the existing literature. The logistic regression model was rerun using the 
transformed categorical variables. Appropriate reference category reflecting minimal risk states 
for each risk factor was identified to be assigned “0” points in the scoring system. For example, 
breastfeeding being a protective factor for SIDS, breastfeeding duration of more than 4 months 
was chosen as a reference category compared to a duration of less than 2 months and 2-4 months. 
An individual infant’s total risk score was calculated by adding up the points for all risk factors. 
4.3 Results 
A thorough literature review showed that there are 8 existing risk score models for SIDS. There 




Table 4.3: Existing SIDS risk scoring system 
Scoring system Risk factors within the 
scoring system 
Study population Prediction 
Oxford score 
(1986)61, 62 
1. Husband’s social class 
at the time of delivery 
2. Marital status 
3. Mother’s age at 




5. Infection during 
pregnancy 
6. Maternal drug 
addiction 
7. Mother took 
barbiturates 
8. Gestation 
9. Multiple births/twins 
10. Previous SIDS 
Using data from the 
Oxford Record Linkage 
Study 
 
Only scoring system 
which provides for some 
interaction between risk 
factors 
 





1. <11 perinatal visits 
2. Male sex 
3. Blue collar family 
4. Birthweight <3000g 
5. Gestational age <40 
weeks 
6. Maternal age <25 
years 
7. Maternal smoking 
8. Pregnancy interval 
<12 months 
Between 1960-1967 
18,999 live-born infants 
in the Kaiser Foundation 
Health Plan.  
 
41 definite SIDS and 
three possible SIDS. The 
diagnosis of SIDS was 
based on Beckwith 
criteria. 
 
Scoring system developed 
based on a review of 
interviews and medical 
chart data of 44 SIDS 
infant and control group. 
Infants with 8 of the 
risk factors had a 
SIDS incidence of 
107/1000 live births 
 
Those with 7 risk 
factors had a SIDS 
incidence of 7/1000 
live births 
Sheffield birth score 
(1978)60, 61 
1. Mother’s age  
2. Previous pregnancies 
3. Twin pregnancy 
4. Duration of second 
stage labor 
5. Mother’s blood group 
6. Birthweight 
7. Feeding intention at 
the time of delivery 
8. Urinary infection 
during pregnancy 
 
Scores were derived after 
a comparison of 195 







Table 4.3 (Cont.) 
Sheffield multistage 
score (1985)64 
1. Mother's age  
2. Birth order  
3. Duration 2nd stage 
labor  
4. Blood group A  
5. Birthweight  
6. Twin  
7. Breastfeeding intention 
at the time of delivery  
8. Urinary infection 
during pregnancy 
Data analysis was carried 
out in 195 cases 




1. Smoking habits of the 
mother 
2. Age of mother at birth 
3. Area of residence 
4. Social class 
5. Antenatal clinic 
attendances (under 3; 3 
or 4; 5-14; 15 or more) 
6. 2nd stage of labor 
(mins) 
7. Employment of mother 
8. Complications of 
pregnancy 
9. Maternal birth injury 
10. Infant feeding 
11. Previous deliveries (#) 
12. Season of birth 
13. Gestation at booking 
14. Sex of infant 
15. Admission to SCBU 
16. Mode of delivery 
17. Birthweight 
18. Multiplicity 
19. Employment of partner 
Based on 99 SIDS cases 
from the 47413 live births 
in the Cardiff Births 
Survey 
21.4% of the 
population was 
categorized as high 
risk. 41.2% of the 
SIDS cases had high-
risk scores 
New Zealand CID 
birth score (1990)63 
1. Maternal age 
2. Parity 
3. Marital status 
4. Infants’ birthweight 
 
Based on 337 possibly 
preventable deaths and 
939 randomly selected 
controls 
Tested on a new 
population of 514 
consecutive births in 
one area in 1986. 49 
SIDS cases occurred. 
 
80% specificity and 
50% sensitivity for 
both the scores 
New Zealand CID 
multistage score 
(1995)63 
1. Maternal age 
2. Parity 
3. Marital status 
4. Infants’ birthweight 
5. Adverse comments on 
the home 
6. Full change in feeding 
method during the 











1. Mother’s age 
2. Parity 
3. Marital status 
4. Birth weight 
 
1 month score 
1. Birth score 
2. Comments on home 
3. Feeding change  
  
 
Current Risk Score Model: 
In the sample, 38% of the infants were female, and 62% were males. All racial/ethnic 
groups were represented in the sample where 42% were Whites, 12% were Blacks, 32% were 
Hispanic, 9% were Asians, and 4% were others.  Among 291 SIDS cases, 62.5% were males, 
and about 72% were Whites (40%) and Hispanics (31.6%) together. A detailed demographic and 
risk factor distribution among the cases and controls are presented in Table 2. All the risk factors 
that were significant at the 0.3 significance level selected for the stepwise regression model are 
also shown in Table 4.4. Other risk factors which did not meet the criteria of p-value less than 











Table 4.4: Descriptive statistics 





































Maternal age at the time of childbirth 
More than or equal to 25 years 












Smoker but not during pregnancy 









































































Breast feeding duration 
More than 4 months 
2-4 months 
































































The most commonly advocated risk factor in ‘back to sleep” campaign, routine sleep 
position was not significant in our typical study population of SIDS infants.  Approximately 
seventy percent of cases and 61% of controls were routinely placed on the stomach to sleep, as 
recommended by pediatricians at that time. About 90% of infants who were routinely placed on 
their stomachs were actually found on their stomachs at the time of death. Nearly 60% of SIDS 
infants with routine sleep position on their back and approximately 68% of SIDS infants with no 
routine sleep position were found on their stomachs at the time of death. 
A summary of the logistic regression model that was developed to predict the risk of 
SIDS is presented in Table 4.5. There were four significant risk factors in the final model. The 
risk factor that was associated with a very high risk of SIDS death was breastfeeding for less 
than 2 months (OR= 15.1, 95% CI 5.83 to 39.17) when compared to those babies who were 
breastfed for more than 4 months. The other three variables, maternal age of less than 25 years at 
the time of childbirth (OR= 1.85, 95% CI 1.21 to 2.83), exposure of the baby to passive smoking 
(OR= 2.51, 95% CI 1.60 to 3.92), and the birth weight of the baby more than 1 SD  below the 
mean (OR= 2.45, 95% CI 1.23 to 4.89) were all associated with significantly increased risk of 
SIDS. The model fit the data well in terms of discrimination (C-statistic= 0.76) and calibration 









Table 4.5: Final Prediction Model for SIDS 
Variable Coefficient Odds Ratio p value 
Birth weight z score 0.89 2.45 (1.23-4.89) 0.011 
Passive smoke 0.92 2.51 (1.60-3.92) <0.001 
Maternal age less than 25 years 0.62 1.85 (1.21-2.83) 0.005 
Breastfeeding duration 
More than 4 months (reference) 
2-4 months 














Based on the final multivariate logistic model, a risk score system was developed to predict an 
infant’s risk for SIDS. Each variable in the model was assigned a score based on beta 
coefficients ranging from 0 to 2 (Table 4.6), and each infants’ score could range from 0 to 6. 
Using a cutoff score of 5 and above for high risk, the risk score had a sensitivity of 100% and a 
positive predictive value of 72.99%. The highest risk score of 6 had a sensitivity of 100% and a 
positive predictive value of 80.33%. For a cuff off criterion of score 1 and lower for low-risk, the 
calculated risk score had a specificity of 100% and a negative predictive value of 92.68%.  
Table 4.6: Risk scoring system for SIDS 
Variable Score 
Birth weight z score 
Less than -1 










Maternal age at the time of childbirth 
More than or equal to 25 years 





More than 4 months (reference) 
2-4 months 










In this study, a risk scoring system was developed to predict the risk of SIDS among 
infants less than 1 year of age using data from a case-control study consisting of 294 cases and 
242 controls. This is the first statistical risk scoring model that was developed from a host of 
maternal and infant characteristics along with environmental factors. The study population 
consisted of a typical SIDS population with a high percentage of males (62%). A number of 
individual risk factors from the triple risk hypothesis were significantly associated with SIDS in 
the univariate analysis of the data. However, the final model consisted of four statistically 
significant predictive variables, birth weight, passive smoking, maternal age at the time of 
childbirth, and breastfeeding duration. Among all SIDS cases, 88.6% of deaths occurred in the 
first 6 months of age, out of which 55.5% of deaths occurred between 2-4 months of age. Hence, 
factors making infants vulnerable to SIDS (low birth weight, young maternal age) in 
combination with the effect of exogenous stressors (passive smoking, breastfeeding) during the 
critical developmental period predicted the risk of SIDS in the current model.  
The point score assigned to each risk factor was derived from a well-fit logistic 
regression model, which included risk factors that were consistent in other published studies. 
There is sufficient existing epidemiological evidence to infer a causal relationship between 
exposure to passive smoke and sudden infant death syndrome.65 Animal and human studies have 
provided evidence on how postnatal exposure to nicotine may affect the neuroregulation of 
breathing and apneic spells, and thus the risk for sudden infant death. Any breastfeeding duration 
(not exclusive) for more than 2 months was significant in this model, after adjusting for 
confounders. It is still unclear how breastfeeding has a protective effect against SIDS. A 
plausible mechanism is that breastfed infants are more easily aroused from sleep than formula-
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fed infants, a phenomenon which is critical in infants with intrinsic vulnerability to SIDS due to 
dysfunctional arousal response.66-69 Low birth weight infants are more prone to SIDS because of 
the prematurity of regulatory pathways of breathing and circulation.70 Higher risk of infants born 
to mothers of age less than 25 years has been attributed to a number of factors including different 
attitudes to child care practices compared to older mothers.71 Teenage pregnancies are itself a 
high risk for low birth weights and are less likely to breastfeed.  
Additional variables that may be relevant to the prediction model that were not tested 
include maternal use of marijuana and other recreational drugs, excessive crying prior to death 
(babies left to soothe themselves), and pregnancy complications. 
Routinely advocated risk factors of routine sleep position and co-sleeping were found to 
be non-significant both independently as well as when adjusted for confounders such as birth 
weight, gestational age, and exposure to passive smoke. These predictors did not improve the 
prediction capability of our logistic model. This is explained by the data used in this study, which 
was collected 28 years ago before the back to sleep campaign. During that time, all parents were 
instructed by their pediatricians to place their babies on their stomachs. Hence, there was a 
similar prevalence (almost identical) of infants routinely placed on their stomach among cases 
and controls. The duration when the data was collected was the appropriate time to assess the 
independent effect of sleep position on SIDS because after the “back to sleep campaign,” 
increased parental awareness about SIDS, as well as changed practices about smoking and 
breastfeeding made it impossible to isolate the independent effect of sleep position and SIDS. 
Another advantage of this dataset is that the interview responses were corroborated with medical 
records (of mothers and babies) and infant death certificates (when applicable), establishing the 
validity and reliability of the data. 
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The major limitation of this prediction risk scoring system is that it was not validated in 
another sample. In the future, the next step would be to assess the external validity of the 
developed risk model in a larger study sample. The current dataset is not big enough to detect the 
statistical effect of all the known risk factors in a multivariate model. The challenge is that the 
data on SIDS is minimal, and the data collection methods, as well as the definition of variables, 
are very heterogeneous across multiple data sets. 
Identifying infants at high risk of SIDS enables parents and clinicians to be more vigilant 
about how to possibly prevent these infant deaths. Furthermore, preventing SIDS in low-risk 
infants will also relieve some anxiety among parents. The advantage of the current risk score 
system is that it does account for the genetic susceptibility due to underlying mutation. 
Therefore, this model has the ability to predict the risk of SIDS without genetic susceptibility 
information which is not routinely accessible to parents and clinicians. Additionally, there is a 
broad spectrum of suspected mutations playing a role in SIDS, and there is no single genetic 
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